


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A quinazoline derivative having the following formula (1) or a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R¹ represents (a) hydroxyl group, (b) an amino group, (c) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, (d) a C₇ and C₁₀ lower aralkylamino group which may be substituted with a COOH group, (e) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (f) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a

COOH group, (k) a C₁ to C₄ lower alkyl group substituted with a COOH group, or (l) a ~~G2 to G4~~ C₂ to C₄ lower alkenyl group which may be substituted with a COOH group;

R² represents (a) a C₁ to C₄ lower alkyl group ~~which may be~~ substituted with a COOH group, a halogen atom, a C₁ to C₄ lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (b) a halogen atom, (c) a hydroxyl group, (d) a C₁ to C₄ lower alkoxy group, (e) an amino group, (f) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (g) a C₇ to C₁₂ aralkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (h) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (i) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (j) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (n) a COOH group or

R³ represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group which may be substituted with a COOH group, a halogen atom, a C₁ to C₄ lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a hydroxyl group, (e) a C₁ to C₄ lower alkoxy group, (f) an amino group, (g) a C₁ to C₄

lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (h) a C₇ to C₁₂ aralkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (i) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (f) an amino group, or (g) a nitro group.

2. (Previously Presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R¹ is a hydroxyl group, an amino group, a C₁ to C₄ lower alkylamino group substituted with a

COOH group, or an amino group acylated with a C₁ to C₄ lower aliphatic acid substituted with a COOH group.

3. (Previously Presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R² is a COOH group.

4. (Currently Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R³ in the formula ~~(4)~~ (1) is a hydrogen atom.

5. (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier therefor.

6. (Currently Amended) A chymase composition inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically acceptable salt according to claim 1, and a pharmaceutically acceptable carrier therefor.

7-13. (Canceled)

14. (Previously Presented) A method for treatment of allergic diseases or rheumatic diseases comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

15. (Previously Presented) A method for treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis or rheumatoid arthritis comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

16. (Previously Presented) A method for treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

17. (Currently Amended) A method for treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, ~~coronary diseases including~~ cardiac infarction, angioendothelia or vascular disorders accompanying arterialization and atheroma comprising administering to a patient in need of such treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

18-19. (Canceled)


20. (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, and a pharmaceutically acceptable carrier therefor.

21. (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 3, and a pharmaceutically acceptable carrier therefor.

22. (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 4, and a pharmaceutically acceptable carrier therefor.

23-25. (Canceled)

26. (Previously Presented) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R^1 represents (a) hydroxyl group, (b) a C_1 to C_4 lower alkylamino group which may be substituted with a COOH group, (c) a C_7 and C_{10} lower aralkylamino group which may be substituted with a COOH group, (d) an amino group acylated with a C_1 to C_4 lower aliphatic acid which may be substituted with a COOH group, (e) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (f) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group sulfonylated with a C_1 to C_4 lower alkanesulfonic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, (j) a C_1 to C_4 lower alkyl group substituted with a COOH group, or (k) a C_2 to C_4 lower alkenyl group which may be substituted with a COOH group;

R^2 and R^3 may be the same or different and represent (a) a hydrogen atom, (b) a C_1 to C_4 lower alkyl group which may be substituted with a COOH group, a halogen atom, a C_1 to C_4 lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a hydroxyl group, (e) a C_1 to C_4 lower alkoxy group, (f) an amino group, (g) a C_1 to C_4 lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C_1 to C_4 lower alkoxy group, (h) a C_7 to C_{12} aralkylamino group which may be substituted with a COOH group, a halogen atom or a C_1 to C_4 lower alkoxy group, (i) an amino group acylated with a C_1 to C_4 lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a

COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (f) an amino group, or (g) a nitro group.

27-28. (Canceled)

29. (Currently Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein said compound is selected from the group consisting of

3-(3-amino-4-chlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,
3-(4-amino-3,5-dichlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-
quinazolinedione,

~~3-(3-amino-4-methylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,~~

4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid

monosodium salt,

3-(3-amino-4-methoxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-

quinazolinedione,

5-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-methoxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-hydroxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid and

4-[(6-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid.

30-31. (Canceled)

32. (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 26 and a pharmaceutically acceptable carrier therefore.

33. (Currently Amended) A chymase composition inhibitor having as an effective ingredient a quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 26 and a pharmaceutically acceptable carrier therefore.